Surmodics goes head-to-head with Medtronic’s drug-coated balloon in pivotal trial

Surmodics (NSDQ:SRDX) announced today that the first patient was enrolled in a pivotal clinical trial evaluating its SurVeil drug-coated balloon.

The 446-patient trial is designed to compare the company’s SurVeil device to Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon as a treatment for peripheral artery disease in the upper leg.

Get the full story at our sister site, Drug Delivery Business News.

The post Surmodics goes head-to-head with Medtronic’s drug-coated balloon in pivotal trial appeared first on MassDevice.

from MassDevice http://ift.tt/2xZQ4vl